

WHAT IS CLAIMED IS:

1. An isolated and/or recombinant monoclonal antibody, which is an antibody or an antibody fragment thereof, wherein the antibody or antibody fragment comprises clone-paired heavy and light chain CDR sequences:
CDRH1, CDRH2 and CDRH3 amino acid sequences of SEQ ID NOs: 124, 125 and 126, respectively and CDRL1, CDRL2 and CDRL3 amino acid sequences of SEQ ID NOs: 208, 209 and 210, respectively .
2. The monoclonal antibody of claim 1, wherein said antibody or antibody fragment is encoded by heavy and light chain variable sequences according to SEQ ID NO:16 and SEQ ID NO:17, respectively.
3. The monoclonal antibody of claim 1, wherein said antibody or antibody fragment is encoded by heavy and light chain variable sequences having at least 70%, 80%, or 90% identity to SEQ ID NO:16 and SEQ ID NO:17, respectively.
4. The monoclonal antibody of claim 1, wherein said antibody or antibody fragment is encoded by heavy and light chain variable sequences having at least 95% identity to SEQ ID NO:16 and SEQ ID NO:17, respectively.
5. The monoclonal antibody of claim 1, wherein said antibody or antibody fragment comprises heavy and light chain variable sequences according to SEQ ID NO:67 and SEQ ID NO:68, respectively
6. The monoclonal antibody of claim 1, wherein said antibody or antibody fragment comprises heavy and light chain variable sequences having 95% identity to SEQ ID NO:67 and SEQ ID NO:68, respectively.
7. The monoclonal antibody of any one of claims 1 to 6, wherein the antibody fragment is a recombinant ScFv (single chain fragment variable) antibody, Fab fragment, F(ab')₂ fragment, or Fv fragment.
8. The monoclonal antibody of any one claims 1 to 6, wherein said antibody is a chimeric antibody, or is bispecific antibody that targets a Chikungunya virus antigen other than glycoprotein.
9. The monoclonal antibody of any one of claims 1 to 6, wherein said antibody is an IgG.

10. The monoclonal antibody of any one of claims 1 to 9, wherein said antibody or antibody fragment further comprises a cell penetrating peptide and/or is an intrabody.
11. A hybridoma encoding an antibody or antibody fragment thereof according to any one of claims 1-10.
12. A method of detecting a Chikungunya virus infection in a subject, comprising conducting a first assay which includes:
 - (a) contacting a sample from said subject with an antibody or antibody fragment thereof according to any one of claims 1-10; and
 - (b) detecting Chikungunya virus glycoprotein E2 in said sample by binding of said antibody or antibody fragment thereof to E2 in said sample.
13. The method of claim 12, wherein said sample is a body fluid.
14. The method of claim 12 or claim 13, further comprising performing steps (a) and (b) a second time and determining a change in the E2 levels as compared to the first assay.
15. A pharmaceutical composition comprising the isolated and/or recombinant monoclonal antibody or antibody fragment thereof according to any one of claims 1-10.
16. Use of an antibody or antibody fragment thereof according to any one of claims 1-10, or the pharmaceutical composition of claim 15, in the preparation of a medicament for delivery to treat or reduce the likelihood of contracting a Chikungunya viral infection in a subject infected with Chikungunya Virus or a subject at risk of contracting Chikungunya virus.
17. The use of claim 16, wherein said medicament is to be administered prior to infection.
18. The use of claim 16, wherein said medicament is to be administered after infection.
19. The use of any one of claims 16-18, wherein delivering comprises antibody or antibody fragment administration, or genetic delivery with an RNA or DNA sequence or vector encoding the antibody or antibody fragment thereof.
20. A cell line producing the isolated and/or recombinant monoclonal antibody or antibody fragment thereof according to any one of claims 1-10.

21. A method of producing the isolated and/or recombinant monoclonal antibody or antibody fragment thereof according to any one of claims 1-10, or the pharmaceutical composition of claim 15, wherein said method comprises the step of:
 - (a) culturing a cell line producing said isolated and/or recombinant monoclonal antibody or antibody fragment thereof;
 - (b) purifying the produced isolated and/or recombinant monoclonal antibody or antibody fragment thereof.
22. The method according to claim 21, wherein the method further comprises the step of formulating said isolated and/or recombinant monoclonal antibody or antibody fragment thereof into a pharmaceutical composition.
23. An isolated and/or recombinant monoclonal antibody or antibody fragment thereof, wherein the antibody or antibody fragment thereof is obtainable by the method of claim 21 or 22.
24. A kit comprising one or more isolated and/or recombinant monoclonal antibody or antibody fragment thereof according to any one of claims 1-10 and optionally packaging material.